B+
Bull case
25%
Probability
Target price
$7.00
+60.2% vs current
NERV
Minerva NeurosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.50
+3.0% vs current
B-
Bear case
30%
Probability
Target price
$2.50
-42.8% vs current
AI sentiment snapshot
Latest data as of 2026-06-22
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+48.0
Score
AI commentary
Recent tone remains mixed to neutral. The main verified operating update is still the May 5, 2026 earnings-related 8-K showing Phase 3 initiation and first-patient screening, while headline volume is low and the only recent news item in the packet is a basic AP earnings snapshot. The deterministic prior remains negative on 20-day to 120-day horizons, analyst revision evidence is unavailable, and peer context is loose, so this still reads as a cautious trial-monitoring setup rather than a high-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-06-22
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystFinancing pressure is lower than before but dilution sensitivity remainsHigh impact
Management said the October 2025 financing provided $80 million upfront, with additional warrant-linked proceeds possible, and stated those funds plus Tranche A exercise proceeds are expected to support Phase 3 completion and NDA resubmission; that reduces immediate survival risk but leaves capital-structure and dilution overhang in the story [#SEC-8K-2026-03-11].
2027-09-30eventConfirmatory Phase 3 execution is now the core value driverHigh impact
Minerva has initiated the global confirmatory Phase 3 MIN-101C19 trial for roluperidone, screened the first patient in March 2026, and continues to point to topline efficacy data in 2H 2027; enrollment pace and trial execution are the main value inflection from here [#SEC-8K-2026-05-05].
2027-12-31catalystRoluperidone remains differentiated but still sits on a single-asset thesisHigh impact
Management continues to frame roluperidone as the only late-stage candidate targeting negative symptoms of schizophrenia, while the open-label olanzapine co-administration update supports background-antipsychotic use assumptions; however, the upside still depends on one late-stage program reaching a successful readout [#SEC-8K-2026-05-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-22 • Updated nightlySource: Internal modelMethodology